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The development of multidrug resistance (MDR) in cancer cells to
chemotherapy drugs continues to be a major clinical problem. MicroRNAs
(miRNA, miR) play an important role in regulating tumour cell growth
and survival; however, the role of miRs in the development of drug resis-
tance in osteosarcoma cells is largely uncharacterized. We sought to iden-
tify and characterize human miRs that act as key regulators of MDR in
osteosarcoma. We utilized a miR microarray to screen for differentially
expressed miRs in osteosarcoma MDR cell lines. We determined the mech-
anisms of the deregulation of expression of miR-15b in osteosarcoma
MDR cell lines, and its association with clinically obtained tumour samples
was examined in tissue microarray (TMA). The significance of miR-15b in
reversing drug resistance was evaluated in a mouse xenograft model of
MDR osteosarcoma. We identified miR-15b as being significantly
(P < 0.01) downregulated in KHOSMR and U-2OSMR cell lines as com-
pared with their parental cell lines. We found that Wee1 is a target gene of
miR-15b and observed that transfection with miR-15b inhibits Wee1
expression and partially reverses MDR in osteosarcoma cell lines. Systemic
in vivo administration of miR-15b mimics sensitizes resistant cells to dox-
orubicin and induces cell death in MDR models of osteosarcoma. Clini-
cally, reduced miR-15b expression was associated with poor patient
survival. Osteosarcoma patients with low miR-15b expression levels had
significantly shorter survival times than patients with high expression levels
of miR-15b. These results collectively indicate that MDR in osteosarcoma
is associated with downregulation of miR-15b, and miR-15b reconstitution
can reverse chemotherapy resistance in osteosarcoma.
1. Introduction
Osteosarcoma is the most common primary bone can-
cer in children and remains a leading cause of cancer
death in adolescents. Standard treatment for osteosar-
coma is surgery and chemotherapy, but treatment
paradigms and survival rates have not improved in
almost three decades (Gill et al., 2013; Isakoff et al.,
2015). Drug treatment usually includes a combination
of doxorubicin, methotrexate and cisplatin. Unfortu-
nately, the efficacy of these agents is hampered by the
eventual development of multidrug resistance (MDR)
(Hattinger et al., 2015; Yang et al., 2014). The mecha-
nism of acquiring MDR in sarcoma is not well under-
stood. Several potential mechanisms, including
overexpression of the MDR1 (ABCB1) gene, which
encodes the ABC drug efflux pump P-glycoprotein
(Pgp), and elevation of the apoptotic threshold that
Abbreviations
MDR, multidrug resistance; miR-15b, microRNA-15b.
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contributes to drug resistance, have been proposed to
play important roles for tumour cells acquiring MDR.
However, the contribution of these mechanisms to
clinical resistance remains controversial (Duan et al.,
2005; Hattinger et al., 2015; Isakoff et al., 2015).
Strategies for reversing MDR by targeting Pgp have
been studied extensively in different MDR model sys-
tems and in clinical trials, including for osteosarcoma,
but have been met with limited results. Reversing drug
resistance is still one of the biggest impediments to
successfully treating osteosarcoma. Recently, experi-
mental evidence from several laboratories has impli-
cated that deregulation of miRs (also known as
microRNAs or miRNAs) may contribute to
chemotherapy drug resistance (Allen and Weiss, 2010;
Holleman et al., 2011; Jones et al., 2012; Kobayashi
et al., 2012; Kovalchuk et al., 2008; Zheng et al.,
2010).
miRs are a subset of small noncoding RNA mole-
cules that influence tumour formation, maintenance,
metastasis, apoptosis and drug resistance (Croce, 2009;
Kobayashi et al., 2012; Kong et al., 2012; Sampson
et al., 2015; Tong and Nemunaitis, 2008). Mature miRs
bind to the 30-untranslated regions (UTRs) of target
genes and inhibit gene expression by degradation or
repressing translation of the target mRNA. More than
1880 annotated human miRs have been registered at
miRBase (release 21.0, http://microrna.sanger.ac.uk/).
There has been a great interest in the function of
miRs in human cancers, including in osteosarcoma.
Numerous studies have observed dysregulation of
miRs in tumours by microarray assay or by RNA
sequencing (Duan et al., 2010, 2011; Kobayashi et al.,
2012). Several studies have demonstrated the involve-
ment of miRs in the pathogenesis of osteosarcoma
with the potential for development in disease diagnos-
tics and therapeutics (Kobayashi et al., 2012; Samp-
son et al., 2015; Zheng et al., 2010). Aberrant
expression of miRs in osteosarcoma is mainly divided
into two classes: upregulated miRs and downregu-
lated miRs. Each individual miR can affect almost
every aspect of tumour cell behaviour, including the
regulation of cellular development, differentiation and
proliferation.
A number of research findings, both laboratory-
and clinic-based, have reported on the implications of
miRs in chemoresistance (Croce, 2009; Gill et al.,
2013; Kobayashi et al., 2012; Ma et al., 2010). Several
research groups have shown that the expressions of
miRs in chemoresistant cancer cells and their parental
chemosensitive ones are significantly different. The sig-
nificant correlation between miR expression patterns
and compound potency in the NCI-60 cancer cell lines
panel suggests that miRs have a role in chemoresis-
tance (Blower et al., 2007). Several miRs have been
shown to sensitize cancer cells that have acquired
MDR to chemotherapy drugs by downregulating
miR-targeted genes (Kobayashi et al., 2012; Koval-
chuk et al., 2008; Sampson et al., 2015; Wang et al.,
2015). Although these studies suggest that miRs have
important roles in the development of chemosensitiv-
ity or chemoresistance in different cancers, including
breast, lung, colon, stomach, liver, ovarian and pros-
tate cancer, the potential role of miRs in the develop-
ment of drug resistance in osteosarcoma is largely
uncharacterized.
To identify the miRs that are important in the
development of drug resistance in osteosarcoma cells,
in this study, we have utilized miR arrays to identify
miRs associated with the development of MDR in two
pairs of osteosarcoma MDR cell lines. Subsequently,
we evaluated the mechanisms of the deregulation of
expression of the most significantly altered miR (miR-
15b) in osteosarcoma MDR cell lines and identified
Wee1 as a miR-15b-targeted gene. Wee1 is a protein
kinase that regulates the G2 checkpoint in response to
DNA damage. Overexpression of Wee1 has been
shown to be correlated with poor outcomes, recurrence
and drug resistance in various cancers (Do et al., 2013;
Hamilton et al., 2014; Kreahling et al., 2013). How-
ever, the association and biological functions of miR-
15b and Wee1 have not yet been investigated in
osteosarcoma. We further examined the expression of
miR-15b and Wee1 in a tissue microarray (TMA)
panel of clinical osteosarcoma samples. The in vivo sig-
nificance of miR-15b in reversing drug resistance was
evaluated in a mouse xenograft model of MDR
osteosarcoma. Finally, we correlated the reduced miR-
15b expression with poor patient survival in patients
with osteosarcoma.
2. Materials and methods
2.1. Human osteosarcoma cell line culture
The human osteosarcoma cell line KHOS and the
drug-resistant osteosarcoma cell line KHOSMR were
kindly provided by Dr. Efstathios Gonos (Institute of
Biological Research & Biotechnology, Athens, Greece)
(Lourda et al., 2007). The human osteosarcoma cell
line U-2OS was purchased from the ATCC, and its
drug-resistant cell line U-2OSMR was generated as pre-
viously reported (Yang et al., 2009a,b). The human
ovarian cancer cell line SKOV-3 and the paclitaxel-
resistant variant SKOV-3TR, the human breast cancer
cell line MCF-7 and the paclitaxel-resistant variant
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MCF-7TR have been described previously (Duan et al.,
2005, 2008). These osteosarcoma, ovarian cancer and
breast cancer drug-resistant cell lines have been char-
acterized with the stable MDR phenotype in previous
studies. All of the cell lines were cultured in RPMI
1640 (Life Technologies, Carlsbad, CA, USA) supple-
mented with 10% FBS, 100 UmL1 penicillin and
100 lgmL1 streptomycin (Life Technologies). Cells
were incubated at 37 °C in a humidified atmosphere,
with 5% CO2–95% air and passaged twice every
2–3 days.
2.2. Human osteosarcoma tissue samples
Frozen tissue samples from 49 patients who had
undergone surgical resection of osteosarcoma were
obtained from the Massachusetts General Hospital
(MGH) sarcoma tissue bank and were studied
according to the policies of the institutional review
board of the hospital. This study was conducted
with the approval of the MGH Institutional Review
Board (IRB protocol #:2007-P-002464/5). All speci-
mens were assessed by light microscopy and
immunohistochemistry.
2.3. Isolation of miRs and miR microarray assay
Total miRs were extracted from cancer cell lines using
the miRNANeasy Mini Kit (Qiagen GmbH, Hilden,
Germany) by following the manufacturer’s instruc-
tions. A similar protocol was used to isolate miRs
from the osteosarcoma frozen tissues. The purity and
quantity of the isolated small miRs were assessed
based on the quality of total RNA using 1% formalde-
hyde–agarose gel electrophoresis and by spectropho-
tometer measurement (Beckman, Columbia, MD,
USA). The miR samples were submitted to LC
Sciences (Houston, TX, USA) for further analysis by
Agilent Bioanalyzer. The miR microarray assay was
performed using a service provider (LC Sciences). The
assay started from a 5-lg total RNA sample, which
was size-fractionated using a YM-100 Microcon cen-
trifugal filter (Millipore, Billerica, MA, USA), and the
small RNAs (< 300 nucleotides) isolated were 30-
extended with a poly(A) tail using poly(A) polymerase.
An oligonucleotide tag was then ligated to the poly(A)
tail for later fluorescent dye staining; two different tags
were used for the two RNA samples in dual-sample
experiments. Hybridization was performed overnight
on a lParaflo microfluidic chip (miRHuman_16.0)
using a microcirculation pump (Atactic Technologies,
Houston, TX, USA). On the microfluidic chip, each
detection probe consisted of a chemically modified
nucleotide coding segment complementary to target
miR (from miRNABase, http://microrna.sanger.ac.uk/
sequences/) or other RNA (control sequences). The
hybridization melting temperatures were balanced by
chemical modifications of the detection probes.
Hybridization used 100 lL 69 SSPE buffer (0.90 M
NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) con-
taining 25% formamide at 34 °C. After RNA
hybridization, tag-conjugating Cy3 and Cy5 dyes were
circulated through the microfluidic chip for dye stain-
ing. Fluorescence images were collected using a laser
scanner (GenePix 4000B; Molecular Devices, Sunny-
vale, CA, USA) and digitized using ARRAY-PRO image
analysis software (Media Cybernetics, Silver Spring,
MD, USA).
2.4. Hierarchical cluster analysis of miR
expression and statistical analysis
Multiple-sample analysis involves normalization, data
adjustment, t-test and clustering. Normalization was
carried out using a cyclic LOWESS (locally weighted
regression) method. The normalization removed sys-
tem-related variations, such as sample amount varia-
tions, different labelling dyes and signal gain
differences of scanners so that biological variations
could be accurately detected. Intensity values were
log2-transformed for further analysis. Gene centring
and normalization transformed the log2 values using
the mean and the SD of individual genes across all
samples using the following formula: Value =
[(Value) – Mean (Gene)]/[SD (Gene)]. For hierarchical
cluster analysis, the clustering was performed using a
hierarchical method and with an average linkage and
Euclidean distance metric. All data processes, except
the clustering plot, were carried out using in-house
(LC Sciences)-developed computer programs. The clus-
tering plot was generated using TIGR MEV (Multiple
Experimental Viewer) software from The Institute for
Genomic Research. For statistical analysis of microar-
ray data, a t-test was performed between the ‘control’
and ‘test’ sample groups. t-values were calculated for
each miR, and P-values were computed from the theo-
retical t-distribution. miRs with P-values below a criti-
cal P-value (typically 0.01) were selected for cluster
analysis.
2.5. Validation and quantification of miR
expression by miR TaqMan reverse transcription
PCR
Real-time reverse transcription PCR (RT-PCR) was
performed to validate differentially expressed miRs in
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osteosarcoma cell lines. Expressions of miR-15b were
determined in osteosarcoma tissues. For mature miR
detection, cDNA reverse transcription was performed
from total RNA samples using specific miR primers
from the TaqMan miR Assay and reagents from the
TaqMan miR Reverse Transcription kit (Life Tech-
nologies, Foster City, CA, USA). The resulting cDNA
was amplified by PCR using TaqMan miR Assay pri-
mers with the TaqMan Universal PCR Master Mix
and analysed with a StepOnePlus Real-Time PCR Sys-
tem (Life Technologies) according to the manufac-
turer’s instructions. Expression of RNU48 miR was
used as an endogenous control. The relative levels of
miR-15b expression were calculated from the relevant
signals by normalization with the signal for RNU48
miR expression. All reactions were performed in tripli-
cate. The relationships between miR-15b expression
levels and clinical features of patients with osteosar-
coma were analysed by chi-square test and Student’s t-
test. The miR-15b expression levels were divided by
the median value. The high-expression group (> 600)
was set above the median value, and the low-expres-
sion group (≤ 600) was set below the median value.
Overall survival curves were analysed with the
Kaplan–Meier method and compared using the log-
rank test. A statistically significant difference was
defined as P-value less than 0.05.
2.6. Evaluation of miR-15b copy number
To determine potential miR-15b copy number varia-
tion between chemoresistance and their parental sensi-
tive cell lines, the TaqMan Copy Number Assay
(Applied Biosystems, Foster City, CA, USA) was per-
formed according to the manufacturer’s protocol.
Briefly, 20 ng of genomic DNA was prepared in a final
volume of 20 lL containing Reference Assay human
RNase P (VIC dye-labelled TAMRATM probe) and
Custom Assay miR-15b (FAMTM dye-labelled NFQ-
MGB probe; probe: 50-CTACAGTCAAGATGCGAA
TCAT-30; FWD: 50-CTGTAGCAGCACATCATGGT
TTAC-30; REV: 50-GAATGAATTTCCTTAAATTTC
TAGAGCAGCAA-30). The absolute quantification
method was used to determine CT data from the
duplex PCR run on the StepOnePlus Real-Time PCR
System. The reaction was run as follows: 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s and
60 °C for 60 s. Afterwards, results were analysed on
COPYCALLER
TM Software v2.0 (Applied Biosystems) with
Manual CT threshold: 0.2; Autobaseline: On; and Pre-
dicted Copy Number: 2. Experiments were carried out
with four replicates. Data were presented as copy
number  SD.
2.7. Transfection with miR-15b precursor (miR-
15b mimics) and transfection with Wee1 siRNA
The human osteosarcoma KHOSMR and U-2OSMR
MDR cells were transfected with LipofectamineTM
RNAiMAX (Life Technologies) and pre-miR-15 pre-
cursor (hsa-miR-15b, Ambion Pre-miRTM miR Pre-
cursor; Ambion, Austin, TX, USA) or nonspecific
control miR precursor according to the manufacturer’s
instructions. These miR-15b precursor molecules
(ready-to-use miR mimics) are small, chemically modi-
fied double-stranded RNA molecules designed to
mimic endogenous mature miR-15b. They enable
detailed study of miR-15b biological effects via gain-
of-function experiments. The sequence of the mature
miR for pre-miR-15b was 50-UAGCAGCA
CAUCAUGGUUUACA-30.
Wee1 knockdown in osteosarcoma cells was per-
formed by transfection with synthetic human Wee1
siRNA (GenBank Accession Number NM_003390,
50-CATGTAACAAGGATCTCCA-30) purchased from
Sigma-Aldrich (St. Louis, MO, USA). Nonspecific
siRNA oligonucleotides were used as negative control.
The siRNA oligonucleotides were dissolved in nucle-
ase-free water at a concentration of 100 mmolL1 and
kept at 20 °C until the following transfection experi-
ment. The effects of Wee1 siRNA on cellular growth
and proliferation were assessed in vitro using the MTT
assay. Experiments were performed in triplicate.
2.8. Chemotherapy drug sensitivity MTT assays
Drug sensitivity was determined using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Sigma-Aldrich) assay. To evaluate the rever-
sal of drug resistance by miR, briefly, osteosarcoma
KHOSMR and U-2OSMR MDR cells were transfected
with miR-15b precursor as described above and pla-
ted in a 96-well plate. Doxorubicin was added in
appropriate concentrations 24 h later. An equivalent
amount of diluent (dimethyl sulfoxide) was added to
culture medium as a negative control. After 96 h of
drug incubation, 20 lL of MTT (20 mgmL1) was
added to each well. After incubation for an addi-
tional 4 h, 200 lL of isopropanol–HCl solution was
added to each well to dissolve the intracellular for-
mazan crystal products. Absorbance was determined
using a 96-well SpectraMax plate reader (Molecular
Devices) at 560 and 650 nm (background). Drugs at
the concentrations utilized in the MTT assay were
performed in the absence of cells to verify no
change in absorbance. Response curves were fitted
using GRAPHPAD PRISM 4 software (GraphPad
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PRISM Software; GraphPad Software, San Diego,
CA, USA).
2.9. Western blot analysis
Total protein from osteosarcoma cell lines was
extracted by 19 RIPA lysis buffer (Upstate Biotechnol-
ogy, Charlottesville, VA, USA). Protein concentration
was determined by the DC Protein Assay (Bio-Rad,
Hercules, CA, USA). Equal amounts of protein were
separated by NuPAGE 4–12% Bis-Tris Gel (Life
Technologies), transferred onto nitrocellulose mem-
brane (Protran; Whatman GmbH, Dassel, Germany)
and incubated with Wee1-specific primary antibodies
(Santa Cruz Biotechnology Inc., Cat# sc-5285, Dallas,
TX, USA, dilution 1 : 1000) and b-actin (Sigma-
Aldrich, dilution 1 : 2000) at 4 °C overnight. The mem-
branes were further probed with respective secondary
antibodies (LI-COR Biosciences, Lincoln, NE, USA)
and scanned by Odyssey CLx imaging equipment (LI-
COR Biosciences) to detect the bands and the density.
Densitometric analysis of western blot results was per-
formed with ImageJ as described in the software’s user
guide. The relative expression of Wee1 was normalized
with respect to actin expression. The western blot was
performed in triplicate.
2.10. Luciferase assay
For luciferase (Luc) activity analysis, osteosarcoma
KHOSMR and U-2OSMR MDR cells were seeded in
96-well plates, and 100 ng of Luc-Wee1-30-UTR repor-
ter vector (SwitchGear Genomics, Menlo Park, CA,
USA) and 40 nM of miR-15 precursor or 40 nM of
nonspecific miR precursor control vectors were
cotransfected with Lipofectamine 3000 (Life Technolo-
gies). Luciferase activity was measured 48 h after
transfection by the LightSwitch Luciferase Assay
ReagentTM (SwitchGear Genomics).
2.11. Establishment of in vivo MDR
osteosarcoma xenograft model and miR-15b
mimic treatment
To determine the effect of restoring miR-15 expression
on reversing drug resistance in osteosarcoma in vivo,
approximately 2 9 106 human osteosarcoma KHOSMR
MDR cells were resuspended in Matrigel (BD Bio-
sciences, San Jose, CA, USA) in a 1 : 1 volume ratio
and injected subcutaneously into the right hind flanks
of 4- to 6-week-old Crl:SHO-PrkdcSCIDHrhr nude mice
(Charles River Laboratories, Ann Arbor, MI, USA).
Two weeks after injection, when the average tumour
volume reached ~ 100 mm3, the mice were randomized
into three groups (N = 10 per group). Group 1 received
injections with sterile saline (0.9% NaCl), group 2 with
2 mgkg1 doxorubicin and group 3 with the combina-
tion of in vivo-ready mirVanaTM miR-15b mimics (Life
Technologies) and doxorubicin (obtained from residual
clinical materials provided by the pharmacy at the
Massachusetts General Hospital). These in vivo-ready
miR mimics are nontoxic and did not induce an
immune response in the animal models tested. miR-15b
mimics were injected via tail vein with Invivofec-
tamine 2.0 Reagent following the manufacturer’s
instructions. Doxorubicin was injected intraperitoneally
with a dose of 2 mgkg1 animal body weight. Two
weeks after injection of KHOSMR MDR cells, when the
average tumour volume reached ~ 100 mm3, saline,
doxorubicin alone or doxorubicin in combination with
in vivo-ready mirVanaTM miR-15b mimics was adminis-
tered twice per week four times. For validation, we also
included a group of mice with osteosarcoma KHOSMR
MDR cells previously transfected with miR-15b precur-
sor, established before subcutaneous injection. Effects
on tumour growth rate were assessed in each mouse by
determining the tumour volume on the day of treat-
ment relative to the tumour volume on day 0. Tumour
volume (mm3) was determined by digital calliper mea-
surements and calculated as W2 9 L/2, where W is
width and L is length. Data are presented as
mean  SD. Animals were killed, once morbidity
became evident or their tumour size exceeded 800 mm3.
Following the indicated treatments, tumour tissues
from the above treated animals were collected and
placed in 10% formalin and embedded in paraffin for
histological analysis. The effects of the miR-15b mimic
treatment on Wee1 expression were determined by
immunohistochemical staining as described above. All
animal studies were in compliance with the protocol
approved by the Massachusetts General Hospital Sub-
committee on Research Animal Care (SRAC) under
the protocol number 2009N000229.
2.12. Osteosarcoma tissue microarray and
immunohistochemistry
The osteosarcoma tissue microarray (TMA) has been
described previously and contains 114 tumour tissues.
The expression levels of Wee1 were determined follow-
ing the immunohistochemistry protocol as previously
reported (Ryu et al., 2010). A similar immunohisto-
chemistry protocol was also used to determine Wee1
expression in osteosarcoma tissues from the mouse
xenograft model. Wee1-positive samples were defined
as those showing nuclear staining pattern in the
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tumour tissues. Wee1 staining patterns were catego-
rized into six groups: 0, no nuclear staining; 1+,
< 10% of cells nuclear-stained positive; 2+, 10–25%
positive cells; 3+, 26–50% positive cells; 4+, 51–75%
positive cells; 5+, > 75% positive cells. The percentage
of cells showing positive nuclear staining for Wee1 was
calculated by reviewing the entire spot. Categorization
of Wee1 staining was completed by two independent
investigators. Discrepant scores between the two inves-
tigators were rescored to obtain a single final score.
2.13. Statistical analyses
Kaplan–Meier survival analysis (GraphPad PRISM)
was used to analyse the correlation between the level
of Wee1 expression and prognosis. Student’s t-test was
used to compare the differences between groups.
Results are given as mean  SD, and values with
P < 0.05 were considered statistically significant.
3. Results
3.1. Identification of differentially expressed miR-
15b in multidrug-resistant osteosarcoma cell
lines KHOSMR and U-2OSMR
To investigate the potential function of miRs in the
development of drug resistance in osteosarcoma, glo-
bal miR expression microarrays were used to analyse
the miR expression profiles in the human osteosar-
coma cell lines KHOS and U-2OS, and their drug-
resistant variants KHOSMR and U-2OSMR. Cluster
analysis revealed that KHOS and U-2OS osteosarcoma
cells with acquired resistance to doxorubicin were
characterized by significant changes in miR expression.
We identified six miR genes (one downregulated miR-
15b and five upregulated miRs) that were the most
dramatically differentially expressed (P < 0.01) in
KHOSMR and U-2OSMR cells compared with their
parental KHOS and U-2OS cells (Fig. 1A). Among
these differentially expressed miRs, miR-15b, which
has been recently shown to be implicated in a number
of human cancers, was the only miR significantly
(P < 0.01) downregulated in both KHOSMR and U-
2OSMR cell lines. As miR-15b was most highly and
concordantly downregulated in more than one
osteosarcoma MDR cell line (both KHOSMR and U-
2OSMR), we further investigated the expression of
miR-15b in the ovarian cancer MDR cell line SKOV-
3TR. The results of miR-15b downregulation obtained
by miR microarray analysis were independently con-
firmed by real-time RT-PCR in these MDR cell lines,
suggesting that the association between miR-15b and
drug resistance is not cell line-specific (Fig. 1B).
The mechanisms underlying miR deregulation in
cancer are not well understood, and the results are
controversial. Because many miRs have been aligned
to genomic fragile sites or in cancer-associated regions,
Fig. 1. Expression of miR-15b is decreased in multidrug-resistant osteosarcoma cell lines. (A) Hierarchical clusters of most significantly
(P < 0.01) altered miRs in drug-sensitive (KHOS, U-2OS) and drug-resistant (KHOSMR, U-2OSMR) osteosarcoma cell lines. miR array of MDR
cell line pairs. Supervised hierarchical clustering of cell lines based on expression of miRs based on multiple-sample analysis for each cell
line. Each column represents a cell line, and each row represents a probe set. The heat maps indicate high (red) or low (green) level of
expression relative to the mean as per the scale shown (the scale below is logarithmic). (B) Confirmation of decreased expression of miR-
15b in a panel of drug-resistant cell lines (KHOSR2, U-2OSMR, SKOV-3TR) as compared with their parental drug-sensitive cell lines by TaqMan
real-time RT-PCR. Bars represent levels of relative expression of miR-15b in each cell line (P < 0.001).
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genome copy abnormalities could involve miR genes.
To determine whether miR-15b copy numbers are
associated with downregulation of miR-15b expression
in osteosarcoma MDR cell lines, we performed the
miR-15b TaqMan Copy Number Assay. The results
showed that the osteosarcoma KHOS cell line had a
higher copy number than the drug-resistant KHOSMR
cell line (2.15  0.07 and 1.75  0.03, respectively).
Human ovarian cancer cell line SKOV-3 also had a
higher copy number than drug-resistant SKOV-3TR
(2.05  0.07 and 1.94  0.06, respectively), suggesting
that copy number changes of miR-15b may at least
partially contribute to miR-15b downregulation in
these MDR cells. However, osteosarcoma cell line U-
2OS had a lower copy number than drug-resistant U-
2OSMR (1.84  0.11 and 2.19  0.04, respectively)
and human breast cancer cell line MCF-7 also had a
lower copy number than the drug-resistant MCF-7TR
(1.89  0.11 and 2.02  0.05, respectively) (Fig. S1).
These data suggest that miR-15b copy number varia-
tion at the genomic DNA level may not control the
expression level of miR-15b in all cell types, but addi-
tional regulatory mechanisms, including epigenetic
changes, such as DNA methylation, or post-transcrip-
tional regulation may also be involved in miR-15b
deregulation. In addition, as many studies cannot iden-
tify a correlation between genomic DNA copy number
and epigenetic changes and expression levels of many
miRs, these data suggest that expression of miR may
be regulated through different mechanisms than those
that regulate expression of mRNA.
3.2. Restoration of miR-15b results in the reversal
of resistance of KHOSMR and U-2OSMR cells to
doxorubicin
The finding that miR-15b expression was downregu-
lated in both drug-resistant osteosarcoma cell lines
KHOSMR and U-2OSMR suggests that loss of miR-
15b expression may contribute to cancer drug resis-
tance; therefore, the restoration of miR-15b expression
in the resistant KHOSMR and U-2OSMR cells may
increase their sensitivity to doxorubicin. To test this
hypothesis, we transfected KHOSMR and U-2OSMR
cell lines with miR-15b precursor (with nonspecific
miR precursor as control) and determined the sensitiv-
ity of cells to doxorubicin treatment. Figure 2A,B
shows that transfection of KHOSMR and U-2OSMR
cells with miR-15b precursor resulted in increased sen-
sitivity of cells to doxorubicin in a dose-dependent
manner, whereas transfection with control nonspecific
miR precursor had no effect on doxorubicin sensitivity
in both cell lines (Fig. 2C,D).
3.3. Wee1 is a direct target of miR-15b in
osteosarcoma cells
Mature miRs bind to the 30-untranslated regions (30-
UTRs) of target genes and inhibit gene expression by
degradation or repression of translation of the target
mRNA. To identify the miR-15b target gene that may
play a role in drug resistance in osteosarcoma, we
employed a number of available computational analy-
sis databases of miR, including microRNA.org and
TargetScan databases, to search for putative binding
sites of miR-15b in the 30-UTR of human gene
mRNAs. One of the top-ranked and highest scoring
gene mRNAs was the Wee1 gene. Further analysis
showed that the predicted alignment of miR-15b tar-
geted two specific sequence sites in the Wee1 mRNA
at nucleotide 265–271 and 544–551 from the start of
the Wee1 30-UTR of 1164 base pairs (Fig. 3A). This
prediction was further confirmed by the MIRGEN soft-
ware. Therefore, Wee1 could be a potential direct tar-
get of miR-15b. To examine whether Wee1 is indeed
functionally targeted by miR-15b, the segment of
Wee1 30-UTR containing the miR-15b complementary
site was cloned into the 30-UTR of a luciferase repor-
ter system. This reporter system was designed to vali-
date predicted miR targets in the 30-UTR of a specific
gene. The resulting Wee1 reporter vector was cotrans-
fected into KHOSMR and U-2OSMR cells with the
miR-15b precursor or the nonspecific miR precursor
that does not have binding sites within the 30-UTR of
Wee1. Figure 3B shows that miR-15b inhibited the
luciferase activity from the construct with the Wee1 30-
UTR segment in both KHOSMR and U-2OSMR cells.
There was no change in the luciferase reporter activity
when the cells were cotransfected with the negative
control nonspecific miR precursor (Fig. 3B) or unre-
lated miRs, such as miR-1 and miR-199a-3p (data not
shown).
3.4. miR-15b significantly inhibits Wee1
expression
To further confirm that miR-15b indeed affects the
protein levels of Wee1 in KHOSMR and U-2OSMR
cells, these cells were transfected with either the miR-
15b precursor (1, 5, 10, 20, or 40 nM) or control non-
specific miR precursor (10, 20 or 40 nM), and the level
of Wee1 was determined by western blot 48 h after
transfection. The results showed that transfection of
KHOSMR and U-2OSMR cells with miR-15b resulted
in a decrease in Wee1 levels, whereas the transfection
with the control nonspecific miR precursor had no
effects on the expression of Wee1 (Fig. 4A,C).
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Quantitative analysis of the western blot data showed
that transfection with miR-15b reduced Wee1 expres-
sion in a dose-dependent manner in both KHOSMR
(Fig. 4B) and U-2OSMR cells (Fig. 4D). In both of
these Pgp-overexpressed KHOSMR and U-2OSMR
MDR osteosarcoma cell lines, transfection with miR-
15b had no effect on Pgp expression (data were not
shown).
3.5. Combination of miR-15b and doxorubicin
treatment reverses drug resistance
To further support the biological significance of the
miR-15b findings in MDR osteosarcoma in vitro, we
subsequently investigated the role of miR-15b in
reversing drug resistance in vivo. The MDR osteosar-
coma cells KHOSMR were either directly grown as
xenografts in nude mice or transfected with miR-15b
precursor prior to subcutaneous injection. The treat-
ment scheme is shown in Fig. 5A. The results revealed
that treatment with saline alone or doxorubicin alone
had no obvious beneficial effects on MDR
osteosarcoma tumour growth suppression in xenograft
models. In contrast, treatment with the combination of
miR-15b and doxorubicin produced a significant inhi-
bitory effect on the growth of the resistant tumours as
compared with control groups (Fig. 5B). The immuno-
histochemical staining indicated a significant decrease
in Wee1 expression in tumours treated with in vivo-
ready mirVanaTM miR-15b mimics and in tumours
established with KHOSMR cells previously transfected
with miR-15b precursor (Fig. 5C). Additionally, on
the basis of animal weight and mortality, no consider-
able toxicity was observed and the animals appeared
to have tolerated miR-15b well in all the treatment
regimens (Fig. S2).
3.6. Wee1 knockdown increases the cytotoxic
effect of doxorubicin
Downregulation of miR-15b-associated Wee1 expres-
sion may participate in the drug resistance in osteosar-
coma. We hypothesized that direct inhibition of the
Wee1 pathway in osteosarcoma cells may lower the
Fig. 2. miR-15b transfection into multidrug-resistant osteosarcoma cells reverses doxorubicin resistance. KHOSMR and U-2OSMR cells were
transfected with either miR-15b precursor or control nonspecific miR precursor and treated with different concentrations of doxorubicin 24 h
after transfection. The relative sensitivity to doxorubicin was determined by MTT analysis 4 days post-treatment. (A, B) Effect of miR-15b
expression on reversing drug resistance in KHOSMR and U-2OSMR cell lines (P < 0.05). (C, D) No effect of nonspecific miR expression on
reversing drug resistance in KHOSMR and U-2OSMR cell lines. Values of absorbance reflect cell survival in miR-15b-transfected and
doxorubicin-treated cells.
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apoptotic threshold and increase chemotherapy sensi-
tivity. To determine whether Wee1 downregulation
influenced the effect of the chemotherapeutic drug
doxorubicin in osteosarcoma cells, KHOSMR and U-
2OSMR cells were transfected with Wee1 siRNA and
then incubated with doxorubicin, a commonly used
first-line chemotherapy drug in the treatment of
osteosarcoma. The combination of Wee1 siRNA and
doxorubicin significantly inhibited cell growth and sur-
vival as compared with those from each treatment
alone in KHOSMR or U-2OSMR cell lines (Fig. S3).
These results showed that the Wee1 knockdown
enhanced the cytotoxic effect of doxorubicin in
osteosarcoma MDR cells.
3.7. miR-15b expression levels correlate with
clinical prognosis in patients with osteosarcoma
To further validate the clinical relevance of miR-15b
expression in patients with osteosarcoma, we deter-
mined miR-15b expression levels and analysed the cor-
relation by a two-sided Student’s t-test to compare the
differences between the survival and nonsurvival
groups of patients with osteosarcoma. A retrospective
study of 49 patients with osteosarcoma from the
MGH sarcoma tissue bank and orthopaedic oncology
databases was surveyed for miR-15b expression analy-
sis. The data on each patient’s age, gender, histological
subtype, metastasis, recurrence, tumour location(s),
follow-up months and disease status were collected.
The expression of miR-15b in the 49 osteosarcoma
samples was then determined by the TaqMan miR
assay. A total of 14 (28.6%) samples from survivors
and 35 (71.4%) samples from nonsurvivors were col-
lected. Comparison of miR-15b expression between the
two groups of patients revealed that miR-15b expres-
sion for samples from nonsurvivors was significantly
lower than that of survivors (P < 0.001). The average
miR-15b expression levels for survivors and nonsur-
vivors were 846 and 526, respectively (Fig. 6A). By
comparing the clinical characteristics of miR-15b-low
(≤ 600) and miR-15b-high (> 600) groups of patients
with osteosarcoma, Kaplan–Meier survival analysis
showed that the outcome for patients in the miR-15b-
low group was significantly worse than for those in the
miR-15b-high group (Fig. 6B). Because miR-15b
inversely regulates Wee1 expression, we also evaluated
whether downregulation of miR-15b in osteosarcoma
samples was correlated with Wee1 upregulation. In
total, 27 frozen osteosarcoma samples with miR-15b
Fig. 3. Wee1 is a direct target of miR-15b in osteosarcoma MDR cells. (A) Computational analysis of miR databases identified Wee1 as a
potential target of miR-15b. Two binding sites of miR-15b exist in the 30-UTR of human Wee1 gene mRNA. (B) Effect of miR-15b
expression on Wee1 driven luciferase activity. KHOSMR and U-2OSMR cells were transfected with a luciferase reporter construct fused to
the Wee1 30-UTR. Subsequently, cells were cotransfected with miR-15b precursor or control nonspecific miR precursor. Luciferase activities
were measured 48 h after transfection using the LightSwitch Luciferase Assay ReagentTM. Values are shown as the percentage of luciferase
expression compared with the controls (P < 0.01).
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expression were evaluated against Wee1 expression
from matched TMA samples for this analysis. The
resulting correlation coefficient and P-value of
r = 0.28 and P < 0.005 indicated that miR-15b
expression was weakly but inversely correlated with
Wee1 expression in osteosarcoma tissues (Fig. S4). We
further analysed the correlation between Wee1 expres-
sion and the prognosis of patients with osteosarcoma
in the osteosarcoma TMA samples. No significant dif-
ference in Wee1 expression was found between the sur-
vivor and nonsurvivor groups (Fig. 6C). The results
also revealed that although there is a trend of higher
(> 3+) Wee1 expression in patients with short-term
survival than lower (≤ 3+) Wee1 expression in patients
with long-term survival, no statistically significant dif-
ference (P > 0.2) in Wee1 expression was identified
between these groups of patients (Fig. 6D).
4. Discussion
Drug resistance is a major cause of cancer progression
during and after treatment with chemotherapy. miRs
have been implicated in the development of drug resis-
tance in various types of human cancers. However, lit-
tle is known about the role of miRs in osteosarcoma
drug resistance. In this study, we used drug-resistant
osteosarcoma MDR cell lines and their parental drug-
sensitive cell lines to investigate the molecular mecha-
nism of resistance and the associated miR changes. We
demonstrate that significantly reduced miR-15b expres-
sion was associated with chemotherapeutic resistance
in osteosarcoma MDR cell lines. miR-15b was the
most significantly downregulated miR identified in
drug-resistant osteosarcoma cell lines by global miR
expression profiles analysis. Although the present
study is solely focused on miR-15b, other upregulated
miRs that were identified in the initial screening of the
osteosarcoma MDR cell lines, including miR-378, may
also be involved in drug resistance. Notably, overex-
pression of miR-378 has been shown to enhance both
cell survival and colony formation and contributed to
drug resistance in glioblastoma cancer cells (Wu et al.,
2012). Expression of miR-574 has also been shown to
be associated with chemoresistance in different cancers
(Ranade et al., 2010; Ujihira et al., 2015).
Several lines of evidence consistently demonstrate
that miR-15b is critical for tumour cell growth, inva-
sion/metastasis, angiogenesis and apoptosis (Lovat
et al., 2015; Xia et al., 2008; Zhao et al., 2016). miR-
15b transfection into tumour cells can decrease tumour
cell proliferation and induce apoptosis (Cimmino
et al., 2005; Xia et al., 2008; Zheng et al., 2013).
Fig. 4. miR-15b transfection into multidrug-resistant osteosarcoma cells suppresses Wee1 expression. (A, C) miR-15b transfection into
osteosarcoma drug-resistant KHOSMR and U-2OSMR cells suppresses Wee1 expression. KHOSMR and U-2OSMR cells were transfected with
either miR-15b precursor or control nonspecific miR precursor in a dose-dependent manner. Expression Wee1 was determined by western
blot 48 h after transfection. b-Actin was used as an endogenous control. (B, D) Western blots from A and C were analysed by densitometry
with ImageJ as described in the Materials and Methods. The relative expression of Wee1 was normalized with respect to actin expression.
The western blot was performed in triplicate as indicated by the error bars. miR-15b significantly inhibits Wee1 expression compared with
controls (P < 0.05).
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However, there are no reports on the use of delivery
of miR-15b in vitro and in vivo for reversing drug
resistance for anticancer therapy. Our study demon-
strated that restoration of miR-15b expression is able
to reverse drug resistance in osteosarcoma cells.
Reduced expression of miR-15b conferred drug resis-
tance traits in part through the modulation of Wee1,
which was validated by target prediction programs
and experimentally in vitro and in vivo. We verified
that miR-15b expression negatively correlated with
Wee1 levels in osteosarcoma cells. Ectopic expression
of miR-15b in osteosarcoma MDR cells reduced the
expression of Wee1, which may contribute to drug
resistance. However, transfection with miR-15b had no
effect on the expression of Pgp in the osteosarcoma
MDR cell lines, suggesting that Wee1 or other Pgp-
independent mechanisms may be responsible for the
miR-15b-associated drug sensitivities. Wee1 is a kinase
that affects the G2-M checkpoint in the cell cycle (Do
et al., 2013). Inhibition of Wee1 has been shown to
Fig. 5. Reversal of doxorubicin resistance in osteosarcoma KHOSMR MDR cells in vivo. (A) A suspension of KHOSMR cells was injected
subcutaneously into the flank of a nude mouse. Two weeks after injection, when the average tumour volume reached ~ 100 mm3, saline,
doxorubicin (2 mgkg1, injected intraperitoneally) alone or doxorubicin in combination with in vivo-ready mirVanaTM miR-15b mimics (injected
via tail vein) were administered twice per week four times. (B) Effects on tumour growth rate were assessed in each mouse by
determining the tumour volume on the day of treatment relative to the tumour volume on day 0. Tumours treated with saline are shown in
blue, tumours treated with doxorubicin alone in red, and tumours treated with a combination of miR-15b mimics and doxorubicin in green
(KHOSMR cells was directly injected subcutaneously and then treated with in vivo-ready mirVana
TM miR-15b mimics by tail vein injection).
KHOSMR tumours previously transfected with miR-15b precursor before subcutaneous injection are shown in pink. Curves for representative
tumour volume per group (N = 10) and tumour volume were presented as mean  SD (*P < 0.05). (C) Histological analysis of the effect of
miR-15b mimics on Wee1 staining in osteosarcoma tumour tissues shows downregulation of Wee1 expression compared with saline or
treatment with doxorubicin alone.
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increase the antitumour activities in the chemotherapy
agents that cause DNA damage (Kreahling et al.,
2012). Several more recent studies have shown that
Wee1 inhibition overcomes drug resistance in different
cancers (Aarts et al., 2015; Hamilton et al., 2014;
Osman et al., 2015).
Previous study has shown that miR-15b expression
suppressed metastasis of drug-resistant tongue cancer
cells in mouse xenograft model (Sun et al., 2012). In
our study, the effect of miR-15b on reversing drug
resistance in vivo in a mouse xenograft model of
drug-resistant osteosarcoma was measured. Without
miR-15b treatment, doxorubicin alone was unable to
suppress drug-resistant osteosarcoma tumour growth.
However, treatment with the combination of miR-15b
and doxorubicin significantly delayed tumour growth
in vivo. Importantly, immunohistochemistry analyses
of these tumours showed decreased levels of Wee1
expression in vivo. Thus, these data suggest that
miR-15b expression is not only a potential prognostic
marker, but also a possible therapeutic target in
osteosarcoma.
The development of drug resistance is a major cause
of cancer recurrence in osteosarcoma. A relapse phe-
notype may be acquired via chemotherapy-induced
selection of a resistant subpopulation or adaptation of
the original tumour cells to therapy drugs. High levels
of miR-15b expression have been found associated
with low risk of recurrence in several types of cancer
(Chung et al., 2010; Sun et al., 2012). Increased
expression of miR-15b in pretreatment osteosarcoma
samples has been demonstrated as the most stringent
predictor of good response to chemotherapy, in which
higher expression of miR-15b in pretreatment samples
correlated with subsequent positive response to
chemotherapy (Jones et al., 2012). Expression levels of
miR-15b in pretreatment specimens also correlate posi-
tively with percentage of necrosis following neoadju-
vant chemotherapy (Jones et al., 2012). In this study,
we evaluated whether there is a correlation between
the level of miR-15b expression and clinical outcome
in osteosarcoma. Comparison of miR-15b expression
showed that miR-15b expression for samples from
nonsurvivors was significantly lower than that of sur-
vivors in osteosarcoma. The outcome for patients in
the miR-15b-low group was significantly worse than
for those in the miR-15b-high group. The data con-
firmed that miR-15b expression levels also correlated
with clinical prognosis, as low expression of miR-15b
is a predictor of poor prognosis in patients. These
results are consistent with previous reports in that
miR-15b levels were found to be significantly lower in
Fig. 6. Correlation of miR-15b and Wee1 with survival of patients with osteosarcoma. (A) Distribution of miR-15b expression in survival and
nonsurvival of osteosarcoma patient samples as determined by real-time RT-PCR (P < 0.001). (B) Analyses of association between
expression of miR-15b (miR-15b low level ≤ 600 and miR-15b high level > 600) and survival in patients with osteosarcoma (P < 0.001). (C)
Distribution of Wee1 expression in survival and nonsurvival of osteosarcoma patient samples as determined by immunohistochemistry
(P > 0.9). (D) Association between expression of Wee1 (Met level ≤ 3+ and Wee1 level > 2+) and survival in patients with osteosarcoma
(P > 0.2). Kaplan–Meier survival analysis was used to analyse the correlation between the level of miR-15b or Wee1 expression and
survival.
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shorter-survival groups as compared with longer-survi-
val groups of patients with tongue cancer or liver can-
cer (Hattinger et al., 2015; Sun et al., 2012).
Several studies have demonstrated that miR-15b and
its downstream targeted genes are dysregulated in
human cancer cells, including in drug-resistant cancer
cells (Allen and Weiss, 2010; Cimmino et al., 2005;
Migliore et al., 2008). miR-15b transfection into can-
cer cells has been shown to lead to decreased expres-
sion of Bcl-2, cyclin E and PIM1 proteins, providing
additional mechanistic explanations of how miR-15b
might play an important role in the development drug
resistance (Migliore et al., 2008; Weirauch et al., 2013;
Xia et al., 2009). Bcl-2 causes chemoresistance in sar-
coma, and chemosensitivity to doxorubicin and cis-
platin can be restored by the Bcl-2 inhibitor ABT-737
(van Oosterwijk et al., 2012). The decrease or loss of
miR-15b expression and the overexpression of Wee1
have been related to invasive growth or tumour stages
in several human cancers (Allen and Weiss, 2010;
Chung et al., 2010; Cimmino et al., 2005; Kreahling
et al., 2012; PosthumaDeBoer et al., 2011; Ryu et al.,
2010; Weirauch et al., 2013). However, the dynamics
and integrity of miR-15b in relation to evolving drug
resistance in osteosarcoma in clinical settings have not
been investigated. We determined the correlation
between expression of miR-15b and Wee1 in osteosar-
coma tissues. The results showed that miR-15b expres-
sion was inversely correlated with Wee1 expression;
expression of miR-15b was lower in osteosarcoma tis-
sues and was coupled with high expression of Wee1.
These results are consistent with studies in other types
of human cancers, such as colorectal tumours, which
also show that miR-15b and Wee1 are often concomi-
tantly deregulated (Zhao et al., 2016). Our study also
showed that miR-15b expression correlated with clini-
cal prognosis in patients with osteosarcoma; the out-
come for patients in the miR-15b-low group was
significantly worse than for those in the miR-15b-high
group. For Wee1 expression, although there was a
trend of higher Wee1 expression in patients associated
with short-term survival than in patients associated
with long-term survival, no statistically significant dif-
ference in Wee1 expression was found between these
groups of patients. The discrepancy between miR-15b
and Wee1 expression for clinical prognosis in osteosar-
coma may relate to multiple potential target genes of
miR-15b. In theory, each miR is believed to interact
with up to 200 potential target genes; a single miR can
regulate multiple oncogenes and oncogenic pathways
that are commonly deregulated in different cancers. As
such, miR-15b has been reported to regulate Wee1,
Bcl-2, cyclin E, cyclin D and/or IGF-1R expression in
several types of cancer, and many of these genes also
play important roles in drug resistance and apoptosis
resistance (Carthew and Sontheimer, 2009; van Ooster-
wijk et al., 2012; PosthumaDeBoer et al., 2011; Wu
et al., 2012; Xia et al., 2009). However, the potential
distinct profile of miR-15b-targeted genes in osteosar-
coma is unknown and further studies are warranted.
More recently, deletion of miR-15b in knockout mice
has been shown to promote B-cell malignancies. miR-
15b/miR-16-2 knockout mice developed B-cell malig-
nancy by age 15–18 months with a penetrance of 60%.
miR-15b/miR-16-2 modulates the cyclin D1, cyclin D2
and IGF-1R genes involved in proliferation and anti-
apoptotic pathways in mouse B cells (Wu et al., 2012).
These data suggest that miR-15b also plays an impor-
tant role in the pathogenesis of B-cell chronic lympho-
cytic leukaemia.
The G2-M DNA damage checkpoint is an impor-
tant cell-cycle checkpoint in eukaryotic organisms
ensuring that cells do not initiate mitosis before they
repair damaged DNA after replication. miR-15b-tar-
geted Wee1 is a tyrosine kinase with a key role as an
inhibitory regulator of the G2-M checkpoint that pre-
cedes entry into mitosis. There is compelling evidence
that abrogation of this checkpoint through Wee1 inhi-
bition may result in increased antitumour activity of
agents that cause DNA damage, such as radiation
therapy or some cytotoxic agents. For example, inhibi-
tion of Wee1 by the selective small-molecule inhibitor
MK1775 can abrogate the G2-M checkpoint, resulting
in premature mitotic entry and initiation of apoptotic
cell death in all sarcoma cells tested. The cytotoxic
effect of Wee1 inhibition on sarcoma cells seems to be
p53 status-independent as all sarcoma cell lines with
different p53 mutations were highly sensitive to
MK1775 treatment. MK1775 significantly enhanced
the cytotoxic effect of gemcitabine in sarcoma cells
lines with different p53 mutational status (Kreahling
et al., 2013). Wee1 inhibition is also effective in
patient-derived sarcoma cells; MK1775 as a single
agent causes significant apoptotic cell death, suggesting
that Wee1 inhibition may represent a novel approach
in the treatment of sarcomas. Wee1 inhibition has also
been shown to sensitize osteosarcoma to radiotherapy
(PosthumaDeBoer et al., 2011).
In conclusion, we demonstrate that miR-15b is
involved in drug resistance in osteosarcoma. We
applied both in vitro and in vivo experimental and clin-
ical findings to observe that miR-15b is reduced in
drug-resistant osteosarcoma cells and tissues, which
affected the chemosensitivity of osteosarcoma cells
maybe partly through the regulation of Wee1. As
miR-15b and its targeted genes, including Wee1 and
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Bcl-2, hold great potential for the treatment of
chemoresistance, this research provides strong evidence
for future development of miR-based therapeutics
strategies directed at treating osteosarcoma. miR-15b-
or miR-15b-targeted gene protein inhibitors may have
a greater therapeutic potential in the treatment of
drug-resistant osteosarcoma when co-administered
with doxorubicin.
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